[
{
	"page":"ENAS5063_1.0.0.0",
	"text":"Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic ESMO CLINICAL PRACTICE GUIDELINES Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi64–72 http://‍annonc.oxfordjournals.org/‍content/‍‍24/‍suppl_6/‍vi64.full.pdf+html Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv22–40 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv22/3958158/mdx224.pdf Familial risk - colorectal cancer: ESMO Clinical Practice Guidelines Balmaña J, Balaguer F, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi73–80 http://annonc.oxfordjournals.org/content/‍24/‍suppl_6/vi73.full.pdf+html Anal cancer: ESMO-‍ESSO-‍ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Glynne-‍Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A and Arnold D Ann Oncol 2014; 25(Suppl 3):iii10-20. http://annonc.oxfordjournals.org/​content/‍25/‍suppl_3/iii10.full.pdf+html   Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Van Cutsem E, Cervantes A, Nordlinger B and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2014; 25 (Suppl 3):iii1-9 http://annonc.oxfordjournals.org/​content/‍25/‍suppl_3/iii1.full.pdf+html ESMO CONSENSUS STATEMENTS ESMO Consensus Guidelines for Management of Patients with Metastatic Colorectal Cancer Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-‍Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-‍Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A and Arnold D Ann Oncol 2016; 27: 1386-422. http://‍annonc.oxfordjournals.org/‍content/‍‍27/8/1386.full.pdf+html ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) and consensus statements on the management of lower gastrointestinal (GI) tumours (early colon cancer, rectal cancer, familial colorectal cancer [CRC] risk, metastatic CRC and anal cancer). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-‍up. The ESMO CPG and consensus statements on lower GI tumours are intended to provide you with a set of recommendations for the best standards of care for lower GI tumours, using evidence-‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-‍based management of lower GI tumours. Please visit http://www.esmo.org or http:/‍/‍oncologypro.esmo.org to view the full guidelines and consensus statements."
},
{
	"page":"ENAS5063_2.1.0.0",
	"text":"Lynch syndrome is the most common hereditary colorectal cancer (CRC) syndrome Accounts for approximately 1–3% of all CRC burden It is transmitted with an autosomal dominant pattern and is associated with mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 These alterations lead to tumour DNA microsatellite instability (MSI) and foster inactivating mutations in tumour suppressors containing microsatellites MMR gene mutations may lead to loss of expression of the corresponding protein, which can be detected by immunohistochemistry (IHC) Mutation carriers have an increased risk of CRC (lifetime risk 30–70%), as well as other cancers, including endometrial, urinary tract, small intestine, ovary, gastric, pancreas, biliary tract, brain and skin cancer Turcot syndrome: Patients with MMR gene mutations and brain tumours Muir-‍Torre syndrome: Patients with cutaneous gland tumours and MMR gene mutations"
},
{
	"page":"ENAS5063_2.2.1.0",
	"text":"Several clinical criteria have been developed for the clinical suspicion of Lynch syndrome Amsterdam Criteria: May lack sensitivity and specificity Bethesda Guidelines: May miss 6–25% of mutation carriers As > 90% of Lynch syndrome CRC cases show MSI and/‍or loss of the corresponding protein by IHC, upfront molecular screening might be a good strategy to identify candidates for germline testing Tumour testing for MSI should be performed in individuals with CRC who are younger than 70 years of age and those who are older than 70 years who fulfil any of the revised Bethesda Guidelines If a tumour with MMR deficiency is detected, germline genetic testing is indicated If loss of MLH1/PMS2 is observed in the tumour, analysis of somatic BRAF V600E mutation or analysis of the methylation of the MLH1 promoter should be performed first to rule out a sporadic case If loss of any of the other proteins (MSH2, MSH6, PMS2) is observed, germline genetic testing should be performed Full germline genetic testing should include DNA sequencing and large rearrangement analysis"
},
{
	"page":"ENAS5063_2.2.2.0",
	"text":"Bethesda guidelines THE REVISED BETHESDA GUIDELINES FOR TESTING COLORECTAL TUMOURS FOR MSI Tumours should be tested for MSI in the following situations: 1 CRC diagnosed in a patient < 50 years of age 2 In the presence of synchronous, metachronous colorectal or other Lynch-‍associated tumours*, regardless of age 3 CRC with the MSI-H histology† diagnosed in a patient < 60 years of age‡ 4 CRC diagnosed in ≥ 1 first-‍degree relative with a Lynch-‍related tumour, with one of the cancers being diagnosed in a patient < 50 years of age 5 CRC diagnosed in ≥ 2 first-‍ or second-‍degree relatives with Lynch-‍related tumours, regardless of age CRC, colorectal cancer; MSI, microsatellite instability; MSI-H, MSI-high *Lynch syndrome-‍related tumours include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract and brain tumours (usually glioblastoma, as seen in Turcot syndrome); sebaceous gland adenomas and keratoacanthomas in Muir-‍Torre syndrome; and carcinoma of the small bowel †Presence of tumour infiltrating lymphocytes, Crohn’s-‍like lymphocytic reaction, mucinous/signet-‍ring differentiation or medullary growth pattern ‡No consensus among the workshop participants on whether to include the age criteria stated in guideline 3 above; participants voted to keep < 60 years of age in the guidelines Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268. By permission of Oxford University Press"
},
{
	"page":"ENAS5063_2.3.0.0",
	"text":"Surveillance CRC: Colonoscopy from age 20–25 years and repeated at 1–2 year intervals is recommended Endometrial and ovarian cancer screening: Gynaecological examination, pelvic ultrasound, CA125 analysis and aspiration biopsy from age 30–35 years and repeated on an annual basis Surveillance for other Lynch-‍associated cancers is not recommended due to the low sensitivity and specificity of the surveillance techniques"
},
{
	"page":"ENAS5063_2.4.0.0",
	"text":"Prevention and treatment Chemoprevention The use of aspirin in the chemopreventive treatment of patients with Lynch syndrome is supported, but the dose and timing of use has not been established Prophylactic surgery There is no data to support carrying out a prophylactic colectomy in healthy mutation carriers and it is not recommended Prophylactic gynaecological surgery may be an option in female mutation carriers from age 35 years and after childbearing is completed Treatment Surgery: The need for intensive surveillance after surgery versus the option of an extended colectomy should be discussed at the time of diagnosis of a CRC, especially in young patients Chemotherapy: Although there is some evidence to suggest that MSI status may be a predictive factor of chemosensitivity (resistance to 5-‍fluorouracil [5-FU] and sensitivity to irinotecan), this is insufficient to allow for recommendations regarding choice of chemotherapy regimen based on MSI status"
},
{
	"page":"ENAS5063_3.1.0.0",
	"text":"FAMILIAL COLORECTAL CANCER x SYNDROME Definition and prevalence This syndrome represents the 40% of families who fulfil the Amsterdam-‍I criteria and who do not exhibit tumour MMR deficiency or a germline MMR gene defect Cancer risk in these families seems to impact only the colorectum The genetic basis of familial colorectal cancer X syndrome has not been identified"
},
{
	"page":"ENAS5063_3.2.0.0",
	"text":"Surveillance Surveillance should include colonoscopy at 3–5 year intervals, starting 5–10 years earlier than the age at diagnosis of the youngest case in the family"
},
{
	"page":"ENAS5063_4.1.0.0",
	"text":"APC-‍ASSOCIATED FAMILIAL ADENOMATOUS POLYPOSIS (FAP) Definition and prevalence Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterised by the presence of multiple adenomas distributed in the colon and rectum Responsible for ≤ 1% of all CRC cases In many patients, extracolonic manifestations are present, especially gastric and duodenal polyps, desmoid tumours, thyroidal and brain tumours, osteomas, congenital hypertrophy of the retinal pigmented epithelium, supernumerary teeth and epidermoid cysts Gardner’s syndrome: Patients with colorectal and extracolonic manifestations Turcot’s syndrome: Patients with colorectal polyposis and brain tumours Findings from a recent cross-‍sectional study suggest an increased number of APC mutations in patients with more adenomas There is a genotype-‍phenotype correlation with potential implications in clinical management (i.e. mutations between codons 1250 and 1464, especially those in codon 1309, are associated with a severe form) In 30–40% of cases, no family history of FAP is present, suggesting a de novo origin"
},
{
	"page":"ENAS5063_4.2.1.0",
	"text":"Diagnosis Overview Clinical diagnosis of classical FAP is based on the identification of > 100 colorectal adenomas A clinical diagnosis of attenuated FAP (AFAP) is often difficult but should be considered in patients with 10–99 adenomas and a later onset of disease APC-‍associated AFAP can mimic MUTYH-‍associated polyposis or sporadic polyp development Examination of multiple family members can help to determine the phenotype Patients with multiple colorectal adenomas (> 10) should be considered for germline genetic testing of APC and/‍or MUTYH Full germline genetic testing of APC should include DNA sequencing and large rearrangement analysis"
},
{
	"page":"ENAS5063_4.3.0.0",
	"text":"Surveillance CRC screening is justified by the disease’s high penetrance Almost all patients with classic FAP will develop a carcinoma by age 40–50 years if the colon is left in place In patients with AFAP, tumours usually appear by age 50–60 years in the absence of intervention Genetic testing allows for screening to be restricted to gene carriers. However, when the causative mutation is not identified, all at-‍risk family members should undergo colorectal screening In families with classic FAP, flexible sigmoidoscopy should be performed Examination should be performed every 2 years, starting at age 12–14 years and continued lifelong in mutation carriers In at-‍risk individuals from families without an identified APC mutation, surveillance should be performed every 2 years until age 40, every 3–5 years between age 40–50 years, and may be discontinued at age 50 years if no polyposis has developed Once adenomas are detected, colonoscopy should be performed annually until colectomy is planned In AFAP cases, colonoscopy is recommended instead of sigmoidoscopy Examination should be performed every 2 years until polyposis is diagnosed Screening should start at age 18–20 years and continue lifelong Once adenomas are detected, colonoscopy should be performed annually Screening for extracolonic manifestations should start when colorectal polyposis is diagnosed or at age 25–30 years, whichever occurs first Gastroduodenal endoscopy should be performed every 5 years until adenomas are detected Regular screening by barium contrast series or wireless capsule endoscopy to detect adenomas in the jejunum and ileum has also been suggested Screening for thyroid cancer should be performed with annual cervical ultrasonography Regular physical examination and abdominal computed tomography (CT) or magnetic resonance imaging (MRI) should be performed in patients with a positive family history of desmoid tumours and those who have had abdominal surgery"
},
{
	"page":"ENAS5063_4.4.0.0",
	"text":"Prevention and treatment Chemoprevention Primary chemoprevention has never been demonstrated to delay the appearance of FAP Secondary chemoprevention with sulindac or celecoxib can be considered as adjuvant therapy when adenoma recurrence is detected after surgery Caution is warranted for the use of COX-2 inhibitors Treatment Surgical resection is the standard of care in patients with classical FAP Endoscopic polypectomy can be considered in some patients with AFAP Surgical resection includes both proctocolectomy with ileal pouch-‍anal anastomosis (IPAA) and total colectomy with ileorectal anastomosis (IRA) The decision on the type of colorectal surgery in FAP depends on: Patient age Severity of rectal polyposis The wish to have children The risk of developing desmoids tumours The site of the mutation in the APC gene IPAA is recommended when a diffuse distribution or severe phenotype is present Total colectomy with IRA can be performed when no or only scarce adenomas are detected in the rectum and a mild familial phenotype is observed, including AFAP Proctocolectomy should be considered in patients reluctant to undergo regular follow-‍up Duodenal adenomas are usually managed with endoscopic polypectomy For patients with advanced disease (Spigelman stage III/‍IV), surgical options include duodenotomy with polypectomy, pancreas-‍sparing duodenectomy and duodenal-‍pancreatectomy Surgical resection of desmoid tumours should be delayed unless complications appear First-‍line treatment of patients with large or growing intra-‍abdominal or abdominal wall tumours is sulindac, usually in combination with tamoxifen, toremifene or raloxifene For intra-‍abdominal tumours not responding to treatment, chemotherapy (e.g. doxorubicin/‍dacarbazine or methotrexate/‍vinblastine) or radiation therapy is indicated The role of surgery on intra-‍abdominal desmoids tumours is controversial"
},
{
	"page":"ENAS5063_4.5.0.0",
	"text":"Follow-‍up Regular endoscopic surveillance every 12 months post-‍surgery is required to detect adenoma recurrence early Some patients with AFAP can be conservatively managed with annual colonoscopy and polypectomy For patients with Spigelman stage I or II duodenal adenomas, upper endoscopy can be performed every 5 to 3 years, respectively Frequency of follow-‍up examinations should be shortened for more advanced stages of disease: Every 1–2 years (Spigelman stage III) or 6 months (Spigelman stage IV)"
},
{
	"page":"ENAS5063_5.1.0.0",
	"text":"MUTYH-‍ASSOCIATED POLYPOSIS Definition and prevalence MUTYH-‍associated polyposis (MAP) is inherited as an autosomal recessive trait with high penetrance Biallelic mutations in the MUTYH gene are responsible for the disorder The frequency of MUTYH heterozygotes in the general European population is 1–1.5%"
},
{
	"page":"ENAS5063_5.2.0.0",
	"text":"Diagnosis Clinically, MAP resembles AFAP Average age of onset is mid 50s Often comprises < 100 adenomas Germ line mutation of the MUTYH gene should be determined in suspected cases"
},
{
	"page":"ENAS5063_5.3.0.0",
	"text":"Surveillance The suggested surveillance protocol for MAP is similar to that for patients with AFAP: Individuals should undergo total colonoscopy every 2 years, starting at age 18–20 years and continuing lifelong Genetic testing allows for screening to be restricted to gene carriers. However, when the causative mutation is not identified, all at-‍risk family members should undergo colorectal screening Upper endoscopy starting at age 25–30 years is recommended (following the same strategy described for APC-‍associated FAP) CRC screening for monoallelic MUTYH carriers is advised"
},
{
	"page":"ENAS5063_5.4.0.0",
	"text":"Chemoprevention ﻿There is no evidence of the usefulness of any primary or secondary chemoprevention strategy in MAP Treatment Clinical management of MAP is similar to AFAP Endoscopic polypectomy can be considered in some patients. However, when polyp burden exceeds the number that could be safely managed by endoscopy, total colectomy with IRA should be offered If rectal polyposis is severe, IPAA is advised Duodenal adenomas are usually managed as in AFAP"
},
{
	"page":"ENAS5063_5.6.0.0",
	"text":"Follow-‍up After total colectomy, regular endoscopic surveillance of the rectum every 12 months is recommended For patients conservatively managed with endoscopic polypectomy, colonoscopy should be performed annually The suggested protocol for surveillance of duodenal adenomatosis in MAP patients is similar to that for AFAP"
},
{
	"page":"ENAS5063_6.1.1.0",
	"text":"Summary of recommendations LYNCH SYNDROME Diagnosis Tumour testing with IHC for MMR proteins and/‍or MSI should be considered in all CRC patients Tumour testing for MSI should be performed in individuals with CRC who are younger than 70 years of age and those who are older than 70 years of age who fulfil any of the revised Bethesda Guidelines If a tumour with MMR deficiency is detected, germline genetic testing is indicated If loss of MLH1/PMS2 is observed in the tumour, analysis of BRAF V600E mutation or analysis of the methylation of the MLH1 promoter should be performed first to rule out a sporadic case If loss of any of the other proteins (MSH2, MSH6, PMS2) is observed, germline genetic testing should be performed (should include DNA sequencing and large rearrangement analysis)"
},
{
	"page":"ENAS5063_6.1.2.0",
	"text":"Surveillance CRC: Colonoscopy from age 20–25 years and repeated at 1–2 year intervals is recommended Endometrial and ovarian cancer screening: Gynaecological examination, pelvic ultrasound, CA125 analysis and aspiration biopsy from age 30–35 years and repeated on an annual basis"
},
{
	"page":"ENAS5063_6.1.3.0",
	"text":"Treatment Prophylactic colectomy in healthy mutation carriers is not recommended Prophylactic gynaecological surgery may be an option in female mutation carriers from age 35 years after childbearing is completed The need for intensive surveillance after surgery versus the option of an extended colectomy should be discussed at the time of diagnosis of a CRC, especially in young patients Choice of chemotherapy regimen should not be based on MSI status"
},
{
	"page":"ENAS5063_6.2.0.0",
	"text":"FAMILIAL COLORECTAL CANCER x SYNDROME The genetic basis of familial colorectal cancer X syndrome has not been identified Surveillance should include colonoscopy at 3–5 year intervals, starting 5–10 years earlier than the age at diagnosis of the youngest case in the family"
},
{
	"page":"ENAS5063_6.3.1.0",
	"text":"APC-‍associated FAP Diagnosis Clinical diagnosis of classical FAP is based on the identification of > 100 colorectal adenomas Diagnosis of AFAP is difficult but should be considered in patients with 10–99 adenomas and a later onset of the disease Patients with multiple colorectal adenomas (> 10) should be considered for germline genetic testing of APC and/‍or MUTYH (should include DNA sequencing and large rearrangement analysis)"
},
{
	"page":"ENAS5063_6.3.2.0",
	"text":"Surveillance In families with classic FAP, flexible sigmoidoscopy should be performed every 2 years, starting at age 12–14 years and continued lifelong in mutation carriers In AFAP cases, colonoscopy is recommended instead of sigmoidoscopy Once adenomas are detected, colonoscopy should be performed annually until colectomy is planned Screening for extracolonic manifestations should start when colorectal polyposis is diagnosed or at age 25–30 years Gastroduodenal endoscopy should be performed every 5 years until adenomas are detected Screening for thyroid cancer should be performed with annual cervical ultrasonography Abdominal CT/‍MRI should be performed in patients with a family history of desmoid tumours"
},
{
	"page":"ENAS5063_6.3.3.0",
	"text":"Surgical resection is the standard of care in patients with classical FAP IPAA is recommended when a diffuse distribution or severe phenotype is present Total colectomy with IRA can be performed when no or only scarce adenomas are detected in the rectum and a mild familial phenotype is observed, including AFAP Endoscopic polypectomy can be considered in some patients with AFAP Proctocolectomy should be considered in patients reluctant to undergo regular follow-‍up Duodenal adenomas are usually managed with endoscopic polypectomy Surgical resection of desmoid tumours should be delayed unless complications appear First-‍line treatment of patients with large or growing intra-‍abdominal or abdominal wall tumours is sulindac plus tamoxifen, toremifene or raloxifene Secondary chemoprevention with sulindac or celecoxib can be considered as adjuvant therapy when adenoma recurrence is detected after surgery"
},
{
	"page":"ENAS5063_44",
	"text":"Regular endoscopic surveillance every 12 months post-‍surgery is required Follow-‍up of duodenal adenomas is according to Spigelman stage"
},
{
	"page":"ENAS5063_6.4.1.0",
	"text":"MUTYH-‍ASSOCIATED POLYPOSIS Diagnosis MAP resembles AFAP (average age of onset is mid 50s, often comprises < 100 adenomas); Germ line mutation of the MUTYH gene should be determined in suspected cases"
},
{
	"page":"ENAS5063_6.4.2.0",
	"text":"Surveillance The suggested surveillance protocol for MAP is similar to that for patients with AFAP Upper endoscopy starting at age 25–30 years is also recommended (following the same strategy described for APC-‍associated FAP) CRC screening for monoallelic MUTYH carriers is advised"
},
{
	"page":"ENAS5063_6.4.3.0",
	"text":"TreatmentClinical management of MAP is similar to AFAPEndoscopic polypectomy can be considered in some patients. However, when polyp burden exceeds the number that could be safely managed by endoscopy, total colectomy with IRA should be offeredIf rectal polyposis is severe, IPAA is advisedThere is no evidence of the usefulness of any primary or secondary chemoprevention strategy"
},
{
	"page":"ENAS5063_6.4.4.0",
	"text":"After total colectomy, endoscopic surveillance of the rectum is recommended annually For patients treated with endoscopic polypectomy, colonoscopy should be performed annually The suggested protocol for surveillance of duodenal adenomatosis is similar to that for AFAP"
},
{
	"page":"ENAS5063_7.0.0.0",
	"text":"Glossary 5-FU 5-‍fluorouracil ACD anal cancer death ADC Apparent Diffusion Coefficient AFAP attenuated familial adenomatous polyposis AJCC American Joint Committee for Cancer APE abdomino-‍‍perineal excision APPA anterior posterior/‍‍posterior anterior BSC best supportive care CA19-9 carbohydrate antigen 19-9 CAPOX capecitabine/‍oxaliplatin cCR clinical complete remission CEA carcinoembryonic antigen CEUS contrast-‍‍enhanced ultrasound cfDNA cell-‍free DNA ChT chemotherapy CIN cervical intra-epithelial neoplasia CLM colorectal liver metastases cN clinical node stage CPGs Clinical Practice Guidelines CRC colorectal cancer CRM circumferential resection margin CRT chemoradiotherapy cT clinical tumour stage CT computed tomography CTC circulating tumour cell ctDNA circulating tumour DNA DCC deleted in colon cancer DFS disease-‍‍free survival dMMR mismatch repair deficient DNA deoxyribonucleic acid DPD dihydropyrimidine dehydrogenase DRE digital rectal examination EAUS endo-‍anal ultrasound EGFR epidermal growth factor receptor EMVI extramural vascular invasion ENE extranodal extension ERCC1 excision repair cross-‍‍complementation group1 ERUS endoscopic rectal ultrasound ESMO European Society for Medical Oncology ESSO European Society of Surgical Oncology ESTRO European Society for Radiotherapy and Oncology EU European Union EUA examination under anaesthesia EURECCA European Registry of Cancer Care FA folinic acid FAP familial adenomatous polyposis FDG fluorodeoxyglucose FDG-‍PET fluorodeoxyglucose positron emission tomography FIT faecal immunochemical test FLOX 5-‍fluorouracil/leucovorin (folinic acid)/‍oxaliplatin FOBT faecal occult blood test FOLFIRI leucovorin/infusional 5-FU/irinotecan FOLFOX leucovorin/infusional 5-FU/oxaliplatin FOLFOXIRI leucovorin/infusional 5-FU/oxaliplatin/irinotecan FP fluoropyrimidine FS flexible sigmoidoscopy G Grade gFOBT guaiac faecal occult blood test GI gastrointestinal H&E hematoxilin and eosin HAART highly active antiretroviral therapy HDR high dose-‍rate HER2 human epidermal growth factor receptor 2 HIPEC hyperthermic intraperitoneal chemotherapy HIV human immunodeficiency virus HPV human papillomavirus IHC immunohistochemistry IMRT intensity-‍modulated radiotherapy IPAA ileal pouch-‍‍anal anastomosis IRA ileorectal anastomosis IV intravenous L lymphatic invasion LARC locally advanced rectal cancer LAT local ablative treatment LND laternal node dissection LPLN lateral pelvic lymph node LRF locoregional failure rate LV leucovorin MAC modified Astler-‍‍Coller classification MAP MUTYH-‍‍associated polyposis mCRC metastatic colorectal cancer MDT multidisciplinary team MMC mitomycin C MMR mismatch repair MRF mesorectal fascia MRI magnetic resonance imaging mriTRG MRI tumour regression grading MSI microsatellite instability MSI-H microsatellite instability high mt mutant NACT neoadjuvant chemotherapy NCCN National Comprehensive Cancer Network NED no evidence of disease OMD oligometastatic disease OS overall survival pCR pathological complete response PET positron emission tomography PET-CT positron emission tomography-computed tomography PNI perineural invasion PS performance status PTEN phosphatase and tensin homologue QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease RCT randomised controlled trial RFA radiofrequency ablation RR response rate RT radiotherapy RTOG Radiation Therapy Oncology Group SBRT stereotactic body radiotherapy SCCA squamous cell carcinoma of the anus SCCAg squamous cell carcinoma antigen SCPRT short-course preoperative radiotherapy SIRT selective internal radiotherapy sm submucosa TACE transarterial chemoembolisation TaTME transanal total mesorectal excision TEM transanal endoscopic microsurgery TGF-α transforming growth factor-‍‍α TGFBR2 transforming growth factor-‍‍beta receptor II Tis carcinoma in situ TME total mesorectal excision TNM tumour node metastasis TRG tumour regression grade TS thymidylate synthase TSER thymidylate synthase enhancer region UGT1A1 uridine diphosphate glucuronosyltransferase 1A1 UICC Union for International Cancer Control US ultrasound V vascular invasion VEGF vascular endothelial growth factor VIN vulval intra-‍‍epithelial neoplasia wt wild-‍type XELOX capecitabine/‍oxaliplatin yp neoadjuvant pathological staging"
}
]